Hype vs Hope of AI in Drug Discovery, a fascinating panel this morning at BiotechX in Basel, ...

Hype vs Hope of AI in Drug Discovery, a fascinating panel this morning at BiotechX in Basel, with participants from Big Pharma and HealthTech, including Bulent Kiziltan, PhD, Hebe Middlemiss, Daniel Kuhn, James Malone, Venkatesh Moktali, PhD, Ivan Griffin

Some core insights:

• The idea of that an AI is just going to spit out new NMEs is clearly more of a hype than a reality, but the potential mid term is still huge

• There a lot of low hanging fruit for AI applications in individual steps in discovery that will have to be rapidly adopted if you want to break the current productivity plateau in research

• You need to address both technology and operating culture at the same time, a technology first approach won't work, you need to create trust with key stakeholders

• Acceleration of drug discovery is just one aspect of the AI impact (an important success metric for AI adoption is for example be able to fail new candidates faster than before) but also making molecules substantially better and more effective